Suppr超能文献

5%氨苯砜凝胶:寻常痤疮治疗中疗效与安全性的综述

Dapsone 5% gel: a review of its efficacy and safety in the treatment of acne vulgaris.

作者信息

Stotland Mira, Shalita Alan R, Kissling Robert F

机构信息

SUNY Downstate Health Sciences Center, Brooklyn, New York, USA.

出版信息

Am J Clin Dermatol. 2009;10(4):221-7. doi: 10.2165/00128071-200910040-00002.

Abstract

Dapsone, a synthetic sulfone that has been available for over 60 years, has been used to treat a myriad of cutaneous disorders. Prior to the general acceptance of isotretinoin, oral dapsone had been reported to be effective in the treatment of nodulocystic acne. However, the potential for systemic toxicity prevented its widespread adoption in the treatment of acne. For many years scientists explored the possibility of developing a topical formulation of dapsone for the treatment of acne in the hope of minimizing the adverse hematologic effects of oral dapsone. Such a formulation had been unavailable until recently. Dapsone 5% gel (Aczone) was recently developed to treat acne vulgaris. This topical formulation was approved in the US based on two randomized, vehicle-controlled studies. A 12-month, open-label study was also conducted to assess the safety and efficacy of topical dapsone over the long term. Finally, two open-label phase I pharmacokinetic studies were conducted to evaluate the systemic absorption of topical dapsone compared with oral dapsone. This article reports the results of these studies, which show a reduction in acne lesion count comparable to those observed in clinical trials of other approved topical acne therapies. With regard to safety, the studies demonstrated that the concentrations of dapsone and N-acetyl dapsone remain low and do not accumulate over time once steady state is reached. Of the total of 50 patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency in all the studies, only two experienced a drop in hemoglobin levels, and those shifts in values were consistent with fluctuations observed for other study participants. A recent study evaluating the risk of hemolysis in patients with G6PD deficiency found topical dapsone 5% gel to be safe to use in this patient population. Based on the observations noted in the above-mentioned studies, we conclude that topical dapsone 5% gel is safe and effective in the treatment of acne vulgaris.

摘要

氨苯砜是一种已上市60多年的合成砜类药物,一直用于治疗多种皮肤疾病。在异维A酸被广泛接受之前,有报道称口服氨苯砜对结节囊肿性痤疮有效。然而,由于其潜在的全身毒性,阻碍了它在痤疮治疗中的广泛应用。多年来,科学家们一直在探索开发氨苯砜局部制剂用于治疗痤疮的可能性,以期将口服氨苯砜的血液学不良反应降至最低。直到最近才有了这样一种制剂。5%氨苯砜凝胶(Aczone)最近被开发用于治疗寻常痤疮。这种局部制剂是基于两项随机、赋形剂对照研究在美国获批的。还进行了一项为期12个月的开放标签研究,以长期评估局部用氨苯砜的安全性和有效性。最后,进行了两项开放标签的I期药代动力学研究,以评估局部用氨苯砜与口服氨苯砜相比的全身吸收情况。本文报告了这些研究的结果,结果显示痤疮皮损数量减少,与其他已获批局部痤疮治疗药物的临床试验结果相当。在安全性方面,研究表明,氨苯砜和N - 乙酰氨苯砜的浓度保持在较低水平,一旦达到稳态,不会随时间累积。在所有研究的总共50例葡萄糖 - 6 - 磷酸脱氢酶(G6PD)缺乏症患者中,只有2例血红蛋白水平下降,且这些数值变化与其他研究参与者观察到的波动一致。最近一项评估G6PD缺乏症患者溶血风险的研究发现,5%局部用氨苯砜凝胶在该患者群体中使用是安全的。基于上述研究中的观察结果,我们得出结论,5%局部用氨苯砜凝胶治疗寻常痤疮安全有效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验